ProCE Banner Activity

FAQs: Clinical Considerations in the Treatment of ITP

Clinical Thought
In this commentary, expert faculty address frequently asked questions on optimizing the management of patients with ITP.

Released: October 10, 2022

Expiration: October 09, 2023

No longer available for credit.

Share

Faculty

David J. Kuter

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Catherine M. Broome

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

Cindy Neunert

Cindy Neunert, MD, MSCS

Associate Professor
Pediatrics, Hematology/Oncology, Stem Cell Transplant
Columbia University Irving Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Dova Pharmaceuticals

Novartis Pharmaceuticals Corporation

Sanofi Genzyme

Program Director Disclosure

Program Director

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

David J. Kuter, MD, DPhil: consultant/advisor/speaker: Actelion, Agios, Alnylam, Amgen, Argenx, BioCryst, Bristol-Myers Squibb, Caremark, CRICO, Daiichi Sankyo, Dova, Genzyme, Immunovant, Incyte, Kyowa-Kirin, Merck Sharp Dohme, Momenta, Novartis, Pfizer, Principis, Protalex, Protalix, Rigel, Sanofi Genzyme, Shionogi, Shire, Takeda, UCB, Zafgen; researcher: Actelion, Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Immunovant, Kezar, Principia, Protalix, Rigel, Takeda, UCB.

Faculty Disclosure

Primary Author

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

Catherine M. Broome, MD: consultant/advisor/speaker: Alexion, Incyte, Sanofi; researcher: Argenx.

Cindy Neunert, MD, MSCS

Associate Professor
Pediatrics, Hematology/Oncology, Stem Cell Transplant
Columbia University Irving Medical Center
New York, New York

Cindy Neunert, MD, MSCS: consultant/advisor/speaker: Janssen, Sobi; researcher: Novartis.